Category Archives: Cell Therapy

Stem Cell Therapy as a Treatment Option for Osteoarthritis Dr. Frank Garcia, board certified orthopedic surgeon with The San Antonio Orthopaedic Group, discusses the use of stem cell therapy in the treatment of osteo... By: The San Antonio Orthopaedic Group … Continue reading →

PUBLIC RELEASE DATE: 25-Aug-2014 Contact: Justin Jackson jjackson@burnsmc.com 212-213-0006 x327 Burns McClellan Santa Monica, CA August 25, 2014 Kite Pharma, Inc., (NASDAQ: KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer, today announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Kite's most advanced product candidate, KTE-C19, is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. The findings from an ongoing Phase 1-2a clinical trial funded by Kite and conducted by the Surgery Branch of the National Cancer Institute (NCI) demonstrated that in 12 out of 13 evaluable patients with advanced B-cell malignancies, administration of anti-CD19 CAR T cells resulted in complete remission in eight patients and partial remission in four patients, representing an overall objective response rate of 92%. Of seven evaluable patients with chemotherapy-refractory DLBCL, four achieved complete remission, three of which are ongoing with durations ranging from … Continue reading →

An Australian-based biomedical company has been given approval from the AFL to use stem-cell therapy on players recovering from injury. Sydney-based Regeneus has revealed it was recently given permission for its HiQCell treatment on players suffering from such issues as osteoarthritis and tendinopathy. The treatment is banned by the World Anti-Doping Agency if it is performance-enhancing but allowed if it is solely to treat injuries. Regeneus commercial development director Steven Barberasaid the regenerative medicine company had sought approval from the AFL for what the company says is "innovative but not experimental" treatment. Advertisement "In 2013, Regeneus sought and received clearance from ASADA [Australian Sports Anti-Doping Authority] for its proprietary HiQCell therapy for use with athletes who participate in sporting competitions subject to the WADA Anti-Doping Code. The AFL is one of many professional sports bodies which applies the WADA Anti-Doping Code within its regulations for players," he said. "In March this year, the AFL introduced a Prohibited Treatments List as an additional level of scrutiny over and above the WADA code for player treatments. In light of this, Regeneus made a submission to the AFL to confirm that our specific treatment is not prohibited under that list. Subsequently, the chief … Continue reading →

Aug. 24, 2014, 2:09 a.m. An Australian-based biomedical company has been given approval from AFL to use stem-cell therapy on players recovering from injury. An Australian-based biomedical company has been given approval from the AFL to use stem-cell therapy on players recovering from injury. Sydney-based Regeneus has revealed it was recently given permission for its HiQCell treatment on players suffering from such issues as osteoarthritis and tendinopathy. The treatment is banned by the World Anti-Doping Agency if it is performance-enhancing but allowed if it is solely to treat injuries. Regeneus commercial development director Steven Barberasaid the regenerative medicine company had sought approval from the AFL for what the company says is "innovative but not experimental" treatment. "In 2013, Regeneus sought and received clearance from ASADA [Australian Sports Anti-Doping Authority] for its proprietary HiQCell therapy for use with athletes who participate in sporting competitions subject to the WADA Anti-Doping Code. The AFL is one of many professional sports bodies which applies the WADA Anti-Doping Code within its regulations for players," he said. "In March this year, the AFL introduced a Prohibited Treatments List as an additional level of scrutiny over and above the WADA code for player treatments. In light of … Continue reading →

Living Cell Technologies Limited CAN: 104 028 042 ASX: LCT OTCQX: LVCLY ASX ANNOUNCEMENT Successful second implant of NTCELL for Parkinsons 18 August 2014 Sydney, Australia and Auckland, New Zealand Living Cell Technologies Limited today announced that a second patient has been successfully implanted at Auckland City Hospital in the clinical trial of the regenerative cell therapy NTCELL for Parkinsons disease. LCT plans to complete the patient treatment phase of the study this year. The Phase I/IIa clinical trial is an open-label investigation of the safety and clinical effects of NTCELL in patients who can no longer respond to current therapy. The trial is directed by Dr Barry Snow MBChB, FRACP, FRCPC, an internationally recognised clinician and researcher in Parkinsons disease who leads the Auckland Movement Disorders Clinic at the Auckland District Health Board. Dr Ken Taylor, CEO of LCT says, A great deal of hard work, preclinical research and scientific endeavour has gone into the discovery and development of NTCELL. Our innovative approach is the first to target regeneration of brain cells for patients who are failing the current conventional treatment for Parkinsons disease. Ends Link: Successful second implant of NTCELL for Parkinsons … Continue reading →

PUBLIC RELEASE DATE: 12-Aug-2014 Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research Mammalian adult central nerve system (CNS) injuries are devastating because of the intrinsic difficulties for effective neuronal regeneration. The greatest problem to be overcome for CNS recovery is the poor regeneration of neurons and myelin-forming cells, oligodendrocytes. Endogenous neural progenitors and transplanted exogenous neuronal stem cells can be the source for neuronal regeneration. However, because of the harsh local microenvironment, they usually have very low efficacy for functional neural regeneration which cannot compensate for the loss of neurons and oligodendrocytes. Glial cells (including astrocytes, microglia, oligodendrocytes and NG2 glia) are the majority of cells in CNS that provide support and protection for neurons. Inside the local microenvironment, glial cells largely influence local and transplanted neural stem cells survival and fates. This review critically analyzes current finding of the roles of glial cells in CNS regeneration, and highlights strategies for regulating glial cells' behavior to create a permissive microenvironment for neuronal stem cells. The Perspectives paper published in Neural Regeneration Research (Vol. 9, No. 13, 2014). ### Article: "Stem cell therapy for central nerve system injuries: glial cells hold the key" by Li Xiao, Chikako Saiki, Ryoji Ide (1 … Continue reading →

Gene and cell therapy By: teresa adell … Continue reading →

mom style food tech home money health crafts More3 Browse Articles & Videos By Category Mark Orwell In the summer of 2003, Mark Orwell began his career as a freelance writer focusing on popular culture, music, and film. He continues to write on a broad array of topics from Miami, Florida. His work has been available in the United States, the Caribbean, and South Africa. The world of medicine continues to grow in leaps and bounds. One of the newest and sometimes controversial procedures is cell therapy. It has been in practice for a while now, but isn't without its growing pains. Like many operations, it may seem radical to people, especially when stem cells are involved. However, the research that has been done shows that cell therapy can be effective in treating a number of ailments. Cell therapy works by introducing new cells into a diseased tissue in order to cure an illness. A number of different cells can be used for various circumstances. Stem cells are cells that have not grown into maturity. When introduced to a tissue, they will grow into healthy cells that match that tissue, thus replacing the ill cells and repairing the tissue. This … Continue reading →

When the scene unfolds Young girls thirteen years old Expose themselves to any Tom, Dick, and Hank Got mo' stretch marks than these hoes Hollin they got rank See Sega ain't in this new world order Them experimenting in Atlanta, Georgia United Nations, overseas They trained assassins to do search and seize Ain't knocking or asking Them coming for niggas like me Po' white trash, like they Tricks like her back in slavery Concentration camps lace with gas pipes lines Inferno's outdoors like they had back When Adolf Hitler was living in 1945 Listen to me now, believe me Later on in the future look it up Where they say it? Ain't no more Constitution In the event of a race war Places like operation heartbreak hotel Moments tear until air tight vents seat off despair Them say expect no mercy Foot you should be my least worries got to deal with Where my W-2's, 10-99's Unmarked black helicopters swoop down And try to put missiles in mines Who's that peeking in my window POW nobody now Me and my family moved in our apartment complex A gate with the serial code was put up next The claim that this … Continue reading →

Year 1 The CIRM Diabetes Disease Team is developing a cell therapy to treat insulin-dependent diabetes. The ultimate goal under CIRM Award DR1-01423 is to file an IND with the FDA to allow first-in-human clinical testing of the cell therapy product. To reach that goal, numerous research and development activities need to be successfully executed in parallel, and the project requires careful planning and agile management. This is particularly critical because the planned product is complex and, as a cutting-edge technology, extends into new regulatory territory. In Year 1 of this Award, virtually all aspects of the project remained on track and the 4-year time line to filing an IND remains the same. The planned product is a combination therapy that is expected to alleviate a diabetics need to perform frequent blood monitoring and insulin injections. It will essentially replace or provide needed support to the endocrine pancreas that is lost or damaged in diabetes. The product consists of a human pancreatic progenitor cell population administered in a durable delivery device. Following administration, the progenitor cells mature into human pancreatic islets including functional insulin-producing glucose-responsive beta cells. Prototypes of the product have been tested in hundreds of rodents, and in … Continue reading →